Showing results (71-80 of 124) with videos related to

Sort By:
Pageof 13
International Journal of Cancer|June 2, 2004
The variant E233G of the RAD51D gene could be a low-penetrance allele in high-risk breast cancer families without BRCA1/2 mutationsRaquel Rodríguez-López, Ana Osorio, Gloria Ribas, et al.
Breast (Edinburgh, Scotland)|August 8, 2024
Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 studyJosé Enrique Alés-Martínez, Judith Balmaña, Pedro Sánchez-Rovira, et al.
European Heart Journal|February 5, 2020
Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registryJosé López-Sendón, Carlos Álvarez-Ortega, Pilar Zamora Auñon, et al.
The Oncologist|October 14, 2022
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL TrialSerena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, et al.
The Lancet. Oncology|September 1, 2023
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 studySara A Hurvitz, Aditya Bardia, Vanesa Quiroga, et al.
Scientific Reports|September 1, 2017
Functional proteomics outlines the complexity of breast cancer molecular subtypesAngelo Gámez-Pozo, Lucía Trilla-Fuertes, Julia Berges-Soria, et al.
Bone|August 10, 2014
Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study)Agustí Barnadas, Luis Manso, Concepción de la Piedra, et al.
The Oncologist|January 21, 2015
Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysisMiguel Martín, Noelia Martínez, Manuel Ramos, et al.
Therapeutic Advances in Medical Oncology|June 18, 2019
Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medicationMeritxell Bellet, Faten Ahmad, Rafael Villanueva, et al.
Plos One|October 21, 2014
The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapyAngelo Gámez-Pozo, Ramón M Pérez Carrión, Luis Manso, et al.
Pageof 13